Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Intralesional interferon-alpha-2b for the treatment of Peyronie's disease

International Journal of Impotence Research volume 14, pages 336–339 (2002)Cite this article

Abstract

Peyronie's disease can best be described as a localized connective tissue disorder that primarily affects the tunica albuginea of the penis. The disease may be attributed to repetitive vascular trauma that initiates an inflammatory process and ultimately leads to the formation of a fibrous penile plaque. The plaque consists mainly of collagen and can significantly alter penile anatomy and function. Patients with Peyronie's disease will most often present with penile curvature, pain on erection, a palpable nodule most commonly located on the dorsal shaft of the penis, and erectile dysfunction. There is no definitive treatment for Peyronie's disease and the treating physician has many options. They may wait for spontaneous resolution of the plaque, choose medical therapy (which includes both oral and intralesional regimens), or opt for surgical management. The main purpose of this article is to discuss the advances in medical therapy for Peyronie's disease, in particular intralesional injection of interferon-alpha-2b (IFN-α-2b). Several studies have concluded that IFN-α-2b can be an effective modality of treatment and that many patients placed on a regimen of IFN-α-2b experienced a significant reduction in penile curvature, diminished pain with erection, and decreased size of the plaque. Further clinical studies are currently being undertaken to determine the precise quantity and frequency of administration of IFN-α-2b that is most effective with the least amount of side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Carson CC . Francoix Gigot de la Peyronie Invest Urol 1981 19: 62–63

    CAS  PubMed  Google Scholar 

  2. Levine LA . Peyronie's disease: a difficult sexual dysfunction problem West J Med 1998 169: 168–169

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease J Urol 1990 144: 1376–1379

    Article  CAS  PubMed  Google Scholar 

  4. Carson CC . Peyronie's disease: medical and surgical management In: Hellstrom WJG, ed Handbook of sexual dysfunction American Society of Andrology: San Francisco 1999 pp 93–98

    Google Scholar 

  5. Scardino PL, Scott WW . The use of tocopherols in the treatment of Peyronie's disease Ann NY Acad Sci 1949 52: 390–401

    Article  Google Scholar 

  6. Yudkin JS . Peyronie's disease in association with metoprolol Lancet 1977 2: 1355

    Article  CAS  PubMed  Google Scholar 

  7. Van de Berg JS et al. Mechanisms in calcification in Peyronie's disease J Urol 1982 127: 52–56

    Article  CAS  Google Scholar 

  8. Somers KD, Winters PA, Dawson DM . Chromosomal abnormalities in Peyronie's disease J Urol 1987 137: 672–676

    Article  CAS  PubMed  Google Scholar 

  9. Jarow JP, Lowe FC . Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction J Urol 1997 158: 1388–1390

    Article  CAS  PubMed  Google Scholar 

  10. Levine LA . Treatment of Peyronie's disease with intralesional verapamil injection J Urol 1997 158: 1395–1399

    Article  CAS  PubMed  Google Scholar 

  11. Chilton CP, Castle WM, Westwood CA, Pryor JP . Factors associated in the etiology of Peyronie's disease Br J Urol 1982 54: 748–750

    Article  CAS  PubMed  Google Scholar 

  12. Nyberg LM, Bias WB, Hochberg MC, Walsh PC . Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens J Urol 1982 128: 48–51

    Article  PubMed  Google Scholar 

  13. Hellstrom WJG, Bivalacqua TJ . Peyronie's disease: etiology, medical, and surgical therapy J Androl 2000 21: 347–354

    CAS  PubMed  Google Scholar 

  14. Roddy TR, Goldstein I, Devine CJ . Peyronie's disease, part I Am Urol Assoc Update Ser 1991 10: 1

    Google Scholar 

  15. Hacshe-Klunder R . Treatment of Peyronie's disease using para-aminobenzoate potassium (Potaba), para-aminobenzoic acid potassium Urologe 1978 17: 224–227

    Google Scholar 

  16. Ralph DJ, Brooks MD, Botazzi GF . The treatment of Peyronie's disease with tamoxifen Br J Urol 1992 70: 648–661

    Article  CAS  PubMed  Google Scholar 

  17. Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study Urology 1994 44: 291–295

    Article  CAS  PubMed  Google Scholar 

  18. Gelbard MK, Lindner A, Kaufman JJ . The use of collagenase in the treatment of Peyronie's disease J Urol 1985 134: 280–283

    Article  CAS  PubMed  Google Scholar 

  19. Gelbard MK, James K, Riach P, Dorey F . Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study J Urol 1993 149: 56–58

    Article  CAS  PubMed  Google Scholar 

  20. Levine LA, Merrick PE, Lee RC . Intralesional verapamil injection for the treatment of Peyronie's disease J Urol 1994 151: 1522–1524

    Article  CAS  PubMed  Google Scholar 

  21. Rehman J, Benet A, Melman A . Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study Urology 1998 51: 620–626

    Article  CAS  PubMed  Google Scholar 

  22. Stuart-Harris RG, Lauchler R . The clinical application of the interferons: a review Med J Aust 1992 156: 869–872

    CAS  PubMed  Google Scholar 

  23. Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta, and -gamma Scand J Urol Nephrol 1991 25: 89–94

    Article  CAS  PubMed  Google Scholar 

  24. Ahuja SK, Sikka SC, Hellstrom WJG . Stimulation of collagen production in an in vitro model for Peyronie's disease Int J Impot Res 1999 11: 207–212

    Article  CAS  PubMed  Google Scholar 

  25. Berman B, Duncan MR . Short-term keloid treatment in vivo with human interferon alpha 2b results in a selective and persistent normalization of keloid fibroblast collagen glycosaminoglycan, and collagenase production in vitro J Am Acad Dermatol 1989 21: 694–702

    Article  CAS  PubMed  Google Scholar 

  26. Benson RC, Knoll LD, Furlow WL . Interferon-alpha-2b in the treatment of Peyronie's disease J Urol 1991 145: 342A

    Article  Google Scholar 

  27. Wegner HE, Andersen R, Knipsel HH, Miller K . Treatment of Peyronie's disease with local interferon-alpha-2b Eur Urol 1995 28: 236–240

    Article  CAS  PubMed  Google Scholar 

  28. Wegner HE, Andersen R, Knipsel HH, Miller K . Local interferon-alpha-2b is not an effective treatment in early stage Peyronie's disease Eur Urol 1997 32: 190–193

    CAS  PubMed  Google Scholar 

  29. Judge IS, Widniewski ZS . Intralesional interferon in the treatment of Peyronie's disease: a pilot study Br J Urol 1997 79: 40–42

    Article  CAS  PubMed  Google Scholar 

  30. Ahuja S et al. A pilot study demonstrating clinical benefit from intralesional interferon-alpha-2b in the treatment of Peyronie's disease J Androl 1999 20: 444–448

    CAS  PubMed  Google Scholar 

  31. Brake M, Loertzer H, Horsch R, Keller H . Treatment of Peyronie's disease with local interferon-alpha-2b Br J Urol 2001 87: 654–657

    Article  CAS  Google Scholar 

  32. Novak TE et al. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease J LA State Med Soc 2001 153: 358–363

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana, USA

    G L Lacy II, D M Adams & W J G Hellstrom

Authors
  1. G L Lacy II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D M Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W J G Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W J G Hellstrom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacy, G., Adams, D. & Hellstrom, W. Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. Int J Impot Res 14, 336–339 (2002). https://doi.org/10.1038/sj.ijir.3900867

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900867

Keywords

This article is cited by

Search

Advanced search

Quick links